AstraZeneca CEO on Vaccine Unit, Covid Endemic Stage

The transcript covers AstraZeneca's sales guidance for 2022, driven by new products in oncology and COVID-19 protection. The company plans to build its COVID-19 division without selling or spinning it off, expecting a decline in vaccine demand but growth in antibodies. The pandemic is transitioning to an endemic phase, requiring ongoing protection for vulnerable groups. CEO Pascal Soriot remains committed to leading AstraZeneca, aiming for leadership in oncology by 2025. Regulatory challenges are discussed, emphasizing the need for diverse clinical trial data.

What percentage growth is AstraZeneca forecasting for 2022?

How does AstraZeneca describe the new targets they have set?

What does Pascal say about the future of the new unit housing COVID-19 assets?

What is the expected trend for AstraZeneca's COVID-19 franchise according to the discussion?

How does Pascal view the current state of the pandemic?

What challenges does AstraZeneca face in the oncology sector?

What is AstraZeneca's approach to the diversity of clinical trials?